الفهرس 
Rheumatoid Arthritis
The disease activity score (DAS).Only 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
SUMMARY AND CONCLUSIONS Rheumatoid arthritis is an inflammatory arthritis that affects nearly 1% of the world‟s adults. It is characterized by symmetric polyarticular inflammation of the synovium, typically of the small joints of the hands (MCP and PIP), wrists and ankles. This inflammation results in pain and stiffness and can lead to progressive joint damage resulting in deformities and loss of function. Associated organ damage also contributes to severe disability causing great impact on the patient„s functional outcomes and health status. The mainstay of RA treatment is the application of DMARDs, which have undergone dramatic changes over the past decade. New and highly effective types have continued to emerge until the most recent years in particular, biological agents that target TNF and other cytokines. Persistent inflammatory mono-arthritis is a common clinical problem and still a challenge for clinicians as it is often difficult to treat; it is a debilitating and destructive condition that may ultimately necessitate joint replacement as a consequence of either acute joint destruction or later secondary osteoarthritis. CCN proteins are key players in organogenesis and inflammation by regulation of inflammatory molecules in astrocyte and promoting the regeneration of central nerve system (CNS), fibrotic diseases and cancer. CCN3 could be detected in RA and OA synovial tissues. Its role in RA remains unknown may be a potential disease activity biomarker for RA. The aim of this study was to evaluate the role of serum level of CCN3 in RA patients and its correlation with disease activity and severity in RA patients.